PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
146.22%
Net income growth above 1.5x VET's 1.26%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
7.73%
Less D&A growth vs. VET's 18.83%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-55.56%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
100.00%
SBC growth while VET is negative at -22.32%. John Neff would see competitor possibly controlling share issuance more tightly.
22.40%
Slight usage while VET is negative at -230.40%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
100.00%
AR growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.40%
Some yoy usage while VET is negative at -230.40%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
72.73%
Well above VET's 67.42%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
104.11%
Operating cash flow growth above 1.5x VET's 0.70%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
28.73%
Some CapEx rise while VET is negative at -149.60%. John Neff would see competitor possibly building capacity while we hold back expansions.
-66.67%
Negative yoy acquisition while VET stands at 100.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-28.73%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-41.54%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
26.70%
Less 'other investing' outflow yoy vs. VET's 180.29%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
19.78%
We have mild expansions while VET is negative at -50.03%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-57.23%
We cut debt repayment yoy while VET is 75.94%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.